Characteristics of the use of metamizole for pain and fever in a Brazilian population: Real-world analysis - REMBRANDT Real-world Evidence Metamizole BRAziliaN DaTabase

Sanofi-Aventis Farmacêutica Ltda.0 个研究点开始时间: 2020年12月2日最近更新: 2023年5月29日

试验速览

暂无简介。

•Cohort 1: metamizole-based cohort
•Any patient active in the system with at least one record of metamizole prescription during the study period.
•Cohort 2: symptoms-based cohort
•-Any active patient in the system with at least one record of headache, migraine or fever between December 1, 2016 and March 31, 2017 or between May 1, 2017 and August 31, 2017.

•Cancer (oncology patients under treatment during the period of the study);
•Rheumatic and autoimmune disorders (Rheumatoid arthritis, Ankylosing spondylitis, Crohn’s disease, Ulcerative colitis, Psoriasis or psoriatic arthritis, Lupus, Fibromyalgia, Osteoarthritis);
•Pregnancy (during the period of the study, not including c-section post-operative use, i.e., metamizole use post-delivery will be included);
•History of metamizole allergy, including anaphylactic reactions;
•Haematological history: bone marrow dysfunction;
•Deficiency of glucose-6-phosphate dehydrogenase (G6PD);
•Had an invalid Amil member identification;
•Denied having used the drug.

发起方

Sanofi-Aventis Farmacêutica Ltda.